Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 July 2025 to Question 64682 on Prostate Cancer: Hormone Treatments, if his Department will publish the Equality and Health Inequalities Impact Assessment for abiraterone acetate plus prednisone for hormone-sensitive non-metastatic prostate cancer.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Equality and Health Inequalities Impact Assessment for abiraterone acetate plus prednisone for hormone-sensitive non-metastatic prostate cancer can be found in the attached document.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of adequacy of the (a) support available to ambulance staff who attend traumatic callouts and (b) suicide prevention training provided to ambulance staff.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The mental health of all National Health Service staff is taken seriously, including ambulance staff as responders to emergency incidents. Ambulance trusts and the Association of Ambulance Trust Chief Executives have worked closely with NHS England to ensure there is a good range of health and wellbeing support for staff. This includes an ambulance sector specific suicide prevention pathway to provide immediate support 24 hours a day, seven days a week for staff experiencing suicidal ideation. At a national level, ambulance trust employees have access to the SHOUT helpline for crisis support, alongside the Practitioner Health service for more complex mental health wellbeing support, including trauma and addiction.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS England’s decision not to commission abiraterone acetate plus prednisone/prednisolone for men with high risk non metastatic prostate cancer on health equity for Black men.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England develops an Equality and Health Inequalities Impact Assessment (EHIA) for policy propositions included in its Policy Work Programme. The EHIA for abiraterone acetate plus prednisone for hormone sensitive non-metastatic prostate cancer noted that incidence rates for prostate cancer are higher in the black ethnic group, compared with the white ethnic group, in males in England. Commissioning decisions for abiraterone acetate plus prednisone/prednisolone apply equally to all individuals with high risk non metastatic prostate cancer regardless of race or ethnicity.
Incidence rates for prostate cancer are higher in the black ethnic group, compared with the white ethnic group, in males in England. To address this inequality, the Government has invested £16 million in the £42 million United Kingdom-wide TRANSFORM trial, led by Prostate Cancer UK, which aims to identify new ways of detecting prostate cancer at an earlier stage, including in men without symptoms. The trial will ensure that at least 10% of participants are Black men, reflecting their higher risk and the importance of ensuring new tests are effective across all groups.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data, published in June 2022, what assessment he has made of the potential implications for his policies of the findings of that study on the cost utility of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in men with newly diagnosed high risk non metastatic prostate cancer.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting evidence to support the routine commissioning of abiraterone in this indication, and it was ranked in the highest priority level. However, at this point in time, it has not been possible to identify the necessary recurrent headroom in revenue budgets to support the funding of any treatments under consideration. This position is being kept under review.
NHS England examined papers from the STAMPEDE trial, including Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data, as part of the review of evidence for the policy proposition.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to update the existing regulations on (a) composition, (b) marketing and (c) labelling of commercial infant and toddler foods to ensure products are suitably nutritious.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Children’s early years provide an important foundation for their future health and strongly influences many aspects of wellbeing in later life.
It is vital that we maintain the highest standards for foods consumed by babies and infants, which is why we have regulations in place that set nutritional and compositional standards for commercial baby food. The regulations also set labelling standards to ensure consumers have clear and accurate information about the products they buy. We continue to keep these regulations under review to ensure they reflect the latest scientific and dietary guidelines.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the NHS 10-year plan will include steps to improve (a) prevention of, (b) early diagnosis for and (c) treatment for lung conditions.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan will deliver the three big shifts our National Health Service needs to be fit for the future: from hospital to community; from analogue to digital; and from sickness to prevention. All of these are relevant to improving respiratory health in all parts of the county.
More tests and scans delivered in the community to allow for earlier diagnosis, better joint working between services, and greater use of apps and wearable technology will all help people manage their long-term conditions, including respiratory conditions, closer to home. Earlier diagnosis of conditions will help people manage their conditions, prevent deterioration, and improve survival rates. Taking action to reduce the causes of the biggest killers, such as enabling a smoke free generation, can further help prevent lung conditions.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the NICE Late Stage Assessment on intermittent catheters on the ambition to move more healthcare out of hospitals and into the community.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department commissions the National Institute for Health and Care Excellence (NICE) to undertake Late-Stage Assessments (LSAs) to help commissioners, clinicians, and patients identify the most effective products that offer the best value for the National Health Service.
The NICE’s LSA of intermittent urethral catheters for chronic incomplete bladder emptying focuses on urethral catheters used in primary care and community settings. This will ensure that as more healthcare is delivered in community settings, commissioners, clinicians, and patients will be better informed when identifying the most effective and best value for money intermittent catheters in a crowded market.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the review of Part IX of the Drug Tariff does not adversely impact investment by the medtech sector.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is working closely with industry through the Drug Tariff Committee to finalise the detail of the update to the product categorisation and listing process of Part IX of the Drug Tariff. The Department remains committed to ensuring that the reforms represent a positive change for patients, the National Health Service, and the medical technology sector. For example, to support innovation and inward investment, a new two-year temporary listing mechanism will be introduced so that innovative products can be made available for patients more quickly.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the review of Part IX of the Drug Tariff supports the NHS 10 Year Plan in shifting care from (a) hospital to the community, (b) treatment to prevention and (c) analogue to digital.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Part IX of the Drug Tariff covers medical technology products prescribed in the community. In 2025, the Department is updating the product categorisation and listing process, following extensive engagement with patient groups, the National Health Service, and industry. The updated categorisation will support the NHS to prescribe the right products for patients. The new listing process will, for the first time, include the patient’s voice and clinical subject matter experts in the decision-making process, and a new temporary listing process will support early access for patients of innovative products able to support the three big shifts.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of NICE’s Late Stage Assessments on the attractiveness of the UK for inward investment from medtech companies.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department commissioned the National Institute for Health and Care Excellence (NICE) to undertake Late-Stage Assessments (LSAs) to help commissioners, clinicians, and patients identify the most effective products that offer the best value for the National Health Service. LSAs benefit health technology manufacturers by giving all manufacturers a transparent, robust, and evidence-based process for demonstrating the added value of their products.